JP2015536347A - 淋菌性ＭｔｒＥペプチドおよびワクチン - Google Patents

淋菌性ＭｔｒＥペプチドおよびワクチン Download PDF

Info

Publication number
JP2015536347A
JP2015536347A JP2015542821A JP2015542821A JP2015536347A JP 2015536347 A JP2015536347 A JP 2015536347A JP 2015542821 A JP2015542821 A JP 2015542821A JP 2015542821 A JP2015542821 A JP 2015542821A JP 2015536347 A JP2015536347 A JP 2015536347A
Authority
JP
Japan
Prior art keywords
mtre
protein
amino acid
seq
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015542821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536347A5 (enExample
Inventor
アン ジェルス
アン ジェルス
アマンダ デッロッコ
アマンダ デッロッコ
Original Assignee
ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド, ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド filed Critical ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
Publication of JP2015536347A publication Critical patent/JP2015536347A/ja
Publication of JP2015536347A5 publication Critical patent/JP2015536347A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015542821A 2012-11-16 2013-11-15 淋菌性ＭｔｒＥペプチドおよびワクチン Pending JP2015536347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727451P 2012-11-16 2012-11-16
US61/727,451 2012-11-16
PCT/US2013/070310 WO2014078656A1 (en) 2012-11-16 2013-11-15 Gonorrheal mtre peptides and vaccines

Publications (2)

Publication Number Publication Date
JP2015536347A true JP2015536347A (ja) 2015-12-21
JP2015536347A5 JP2015536347A5 (enExample) 2017-01-05

Family

ID=50731717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542821A Pending JP2015536347A (ja) 2012-11-16 2013-11-15 淋菌性ＭｔｒＥペプチドおよびワクチン

Country Status (6)

Country Link
US (2) US9902756B2 (enExample)
EP (1) EP2919806A4 (enExample)
JP (1) JP2015536347A (enExample)
AU (1) AU2013344571A1 (enExample)
CA (1) CA2891552A1 (enExample)
WO (1) WO2014078656A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541671A (ja) * 2020-09-17 2023-10-03 プロシーナ バイオサイエンシーズ リミテッド シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10900043B2 (en) 2014-09-02 2021-01-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating bacterial disease
WO2016036839A1 (en) * 2014-09-02 2016-03-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating gonorrhea
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
GB202214756D0 (en) * 2022-10-07 2022-11-23 Univ Oxford Innovation Ltd Product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001011096A (ja) * 1999-06-28 2001-01-16 Maruho Co Ltd 淋菌に対するヒト抗体
JP2008263973A (ja) * 2001-02-12 2008-11-06 Chiron Srl 淋菌性タンパク質および淋菌性核酸

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008981A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. METHODS FOR IDENTIFICATION AND ISOLATION OF SPECIFIC NUCLEOTIDE SEQUENCES IN cDNA AND GENOMIC DNA
EP2261345A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
BR0015137A (pt) * 1999-10-29 2003-03-25 Chiron Spa Peptìdeos antigênicos de neisseria
CN102869782B (zh) 2010-03-01 2015-11-25 生化学工业株式会社 细菌产生软骨素的组合物和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001011096A (ja) * 1999-06-28 2001-01-16 Maruho Co Ltd 淋菌に対するヒト抗体
JP2008263973A (ja) * 2001-02-12 2008-11-06 Chiron Srl 淋菌性タンパク質および淋菌性核酸

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"E2PFI6", UNIPROT[ONLINE], JPN6017032566, 30 November 2010 (2010-11-30), ISSN: 0003980934 *
"Q51006", UNIPROT[ONLINE], JPN6018022150, 1 November 1996 (1996-11-01), ISSN: 0003817779 *
"安定したタンパク質抽出と効率的なサンプル調製に", メルク株式会社, JPN6018022155, 26 July 2012 (2012-07-26), ISSN: 0003980941 *
COLE, J.G. ET AL.: "Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops", PLOS ONE, vol. Vol. 4, e8108, JPN6017032562, 2009, pages 1 - 11, ISSN: 0003629078 *
CORNELISSEN, C. N. ET AL.: "TonB-Dependent Transporters Expressed by Neisseria gonorrhoeae", FRONT. MICROBIOL., vol. 2, JPN6018022144, 2011, pages 117 - 1, ISSN: 0003980937 *
DELAHAY, R. M. ET AL.: "Involvement of the gonococcal MtrE protein in the resistance of Neisseria gonorrhoeae to toxic hydro", MICROBIOLOGY, vol. 143, JPN6018022140, 1997, pages 2127 - 2133, ISSN: 0003980936 *
ENDO, T. ET AL.: "Rabbit antibodies toward extracellular loops of the membrane spanning region of human thyrotropin re", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 181, JPN6018022147, 1991, pages 1035 - 1041, XP024838016, ISSN: 0003980939, DOI: 10.1016/0006-291X(91)92041-H *
PLANTE, M. ET AL.: "Intranasal immunization with gonococcal outer membrane preparations reduces the duration of vaginal", J. INFECT. DIS., vol. 182, JPN6017032564, 2000, pages 848 - 855, ISSN: 0003817778 *
WARNER, D.M. ET AL.: "Regulation of the MtrC-MtrD-Mtr Eefflux-pump system modulates the in vivo fitness of Neisseria gonor", J. INFECT. DIS., vol. 196, JPN6017032559, 2007, pages 1804 - 1812, ISSN: 0003980935 *
ZHU, W. ET AL.: "Vaccines for gonorrhea: can we rise to the challenge?", FRONT. MICROBIOL., vol. Vol. 2, Article 124, JPN6017032561, 2011, pages 1 - 13, ISSN: 0003817777 *
土屋 友房 ほか: "膜タンパク質可溶化剤の進歩", 油化学, vol. 37, JPN6018022153, 1998, pages 386 - 393, ISSN: 0003980940 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541671A (ja) * 2020-09-17 2023-10-03 プロシーナ バイオサイエンシーズ リミテッド シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン

Also Published As

Publication number Publication date
WO2014078656A1 (en) 2014-05-22
US20150291666A1 (en) 2015-10-15
US10414805B2 (en) 2019-09-17
EP2919806A4 (en) 2016-06-22
US9902756B2 (en) 2018-02-27
CA2891552A1 (en) 2014-05-22
EP2919806A1 (en) 2015-09-23
US20190077837A1 (en) 2019-03-14
AU2013344571A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
US7851609B2 (en) Chlamydia PMP proteins, gene sequences and uses thereof
US10414805B2 (en) Gonorrheal MtrE peptides and vaccines
JP6377907B2 (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原
JP2001517069A (ja) 結核の免疫治療および診断のための化合物および方法
EP3312192B1 (en) Immunogenic compositions containing bacterial outer membrane vesicles
JP2002503683A (ja) 結核の免疫療法および診断のための化合物および方法
US20040071731A1 (en) Chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
SG176220A1 (en) Casb7439 constructs
JP2000125889A (ja) アクチノバチルス・プレウロニウモニアからのタンパク質
JP2023025066A (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
US7537772B1 (en) Chlamydia protein, gene sequence and the uses thereof
JP2004520825A (ja) ヘリコバクタータンパク質、核酸およびその使用
JP2024504195A (ja) クラミジア・トラコマチス抗原性ポリペプチドおよびワクチン目的のためのその使用
US20180153990A1 (en) Pca1 protein and methods of treating pneumocystis pneumonia infection
JP2024500237A (ja) 抗原提示細胞に対するｍｏｍｐ ｖｓ４抗原の標的化に基づくクラミジアワクチン
US20030017162A1 (en) Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
JP2005514052A (ja) Ｂ群連鎖球菌の新規の細胞表面プロテアーゼの使用
WO2025116751A1 (en) Multivalent vaccine compositions
JP2002524034A (ja) Ｃｈｌａｍｙｄｉａ抗原および対応するＤＮＡフラグメントおよびそれらの使用
AU2002246667A1 (en) Helicobacter proteins, nucleic acids and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190226